LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "ven aza" as a keyword



Photo by mangster from unsplash

Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine

Sign Up to like & get
recommendations! Published in 2022 at "Open Forum Infectious Diseases"

DOI: 10.1093/ofid/ofac486

Abstract: Abstract Background Acute myeloid leukemia (AML) is associated with poor prognosis, particularly in elderly patients with comorbidities. Combining azacitidine (AZA) with BCL-2 inhibitor venetoclax (VEN) demonstrated significant improvement in outcomes for newly-diagnosed AML patients compared… read more here.

Keywords: ven aza; myeloid leukemia; incidence; incidence invasive ... See more keywords

Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy

Sign Up to like & get
recommendations! Published in 2020 at "Blood"

DOI: 10.1182/blood-2020-138821

Abstract: Venetoclax and azacitidine (ven/aza) is our institutional preference for initial treatment of non-core binding factor AML patients age ≥60. Given potential durability of response in these patients, the role of transplant (SCT) in patients who… read more here.

Keywords: response; consult; consultancy; ven aza ... See more keywords
Photo from wikipedia

Venetoclax and Azacitidine Compared to Induction Chemotherapy for Newly Diagnosed Patients with Acute Myeloid Leukemia.

Sign Up to like & get
recommendations! Published in 2021 at "Blood advances"

DOI: 10.1182/bloodadvances.2021005538

Abstract: Venetoclax (ven) + azacitidine (aza) is the standard of care for newly-diagnosed acute myeloid leukemia (AML) patients who are not candidates for intensive chemotherapy (IC). Some patients who are IC candidates instead receive ven/aza. We… read more here.

Keywords: chemotherapy; newly diagnosed; myeloid leukemia; ven aza ... See more keywords
Photo by mangster from unsplash

Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.

Sign Up to like & get
recommendations! Published in 2021 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2021.39.15_suppl.7011

Abstract: 7011 Background: Patients (pts) with therapy-related myeloid neoplasms (tMN), antecedent myelodysplastic syndrome, or antecedent myelodysplastic/myeloproliferative neoplasms (A-MDS/MPN) may have poor outcomes due to age and adverse genetic/karyotypic features. In the VIALE-A study, pts with tMN… read more here.

Keywords: chemotherapy; ven aza; tmn mds; mds mpn ... See more keywords
Photo by mangster from unsplash

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients

Sign Up to like & get
recommendations! Published in 2022 at "Cancers"

DOI: 10.3390/cancers14082025

Abstract: Simple Summary The combination of venetoclax and azacititine (VEN–AZA) has recently been approved for the treatment of unfit newly diagnosed (ND) acute myeloid leukemia (AML) patients. Few data are available for the relapsed and/or refractory… read more here.

Keywords: ven aza; aml patients; leukemia; group ... See more keywords